SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q-myelodysplastic syndrome

被引：0
|
作者：
K Siva
P Jaako
K Miharada
E Rörby
M Ehinger
G Karlsson
S Karlsson
机构：
[1] Lund Strategic Center for Stem Cell Biology,Department of Molecular Medicine and Gene Therapy
[2] University Hospital,undefined
来源：
Leukemia | 2012年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2416 / 2419
页数：3
相关论文
共 22 条
  • [1] SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q-myelodysplastic syndrome
    Siva, K.
    Jaako, P.
    Miharada, K.
    Rorby, E.
    Ehinger, M.
    Karlsson, G.
    Karlsson, S.
    LEUKEMIA, 2012, 26 (11) : 2416 - 2419
  • [2] 5Q-MYELODYSPLASTIC SYNDROME (MDS) MASQUERADING AS DIAMOND BLACKFAN ANEMIA (DBA)
    Vlachos, Adrianna
    Farrar, Jason
    Atsidaftos, Evangelia
    Muir, Ellen
    Markello, Thomas C.
    Singh, Sharon
    Liu, Johnson M.
    Ellis, Steven R.
    Arceci, Robert J.
    Bodine, David
    Lipton, Jeffrey
    PEDIATRIC BLOOD & CANCER, 2012, 58 (07) : 1073 - 1074
  • [3] LENALIDOMID INFLUENCES THE T-CELL RECEPTOR REPERTOIRE IN PATIENTS WITH 5Q-MYELODYSPLASTIC SYNDROME
    Momot, T.
    Dobbelstein, C.
    Koenig, J.
    Schulz, O.
    Pautsch, J. -E.
    Ganser, A.
    Weissinger, E. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 274 - 274
  • [4] Influence of lenalidomide treatment on the T-cell receptor repertoire in patients with 5q-myelodysplastic syndrome
    Momot, T.
    Koenig, J.
    Ganser, A.
    Weissinger, E. M.
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (09) : 70 - 70
  • [5] Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis
    Giv, Mahsa Jafari
    Yoosuff, Alam
    Bazargan, Ali
    CHEST, 2015, 148 (02) : E35 - E37
  • [6] Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome
    Messingerova, Lucia
    Jonasova, Anna
    Barancik, Miroslav
    Polekova, Lenka
    Seres, Mario
    Gibalova, Lenka
    Breier, Albert
    Sulova, Zdena
    GENERAL PHYSIOLOGY AND BIOPHYSICS, 2015, 34 (04) : 399 - 406
  • [7] Effect of lenalidomide therapy on the levels of P-glycoprotein, MRP and matrix metalloproteinases in patients with 5q-myelodysplastic syndrome
    Messingerova, L.
    Barancik, M.
    Jonasova, A.
    Seres, M.
    Gibalova, L.
    Breier, A.
    Sulova, Z.
    LEUKEMIA RESEARCH, 2013, 37 : S108 - S109
  • [8] Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
    Ximeri, Maria
    Galanopoulos, Athanasios
    Klaus, Mirjam
    Parcharidou, Agapi
    Giannikou, Krinio
    Psyllaki, Maria
    Symeonidis, Argyrios
    Pappa, Vasiliki
    Kartasis, Zafiris
    Liapi, Dimitra
    Hatzimichael, Eleftheria
    Kokoris, Styliani
    Korkolopoulou, Penelope
    Sambani, Constantina
    Pontikoglou, Charalampos
    Papadaki, Helen A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03): : 406 - 414
  • [9] Anti-proliferative activity of CC-5013 in 5q-myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines.
    Gandhi, AK
    Naziruddin, S
    Verhelle, D
    Brady, H
    Schafer, P
    Stirling, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 587S - 587S
  • [10] LOSS OF THE RED CELL B ANTIGEN AND BLOOD GROUP CHANGE IS NOT ASSOCIATED WITH METHYLATION OF THE ABO GENE PROMOTER REGION IN A PATIENT WITH 5Q-MYELODYSPLASTIC SYNDROME
    Martinez, A.
    Kuniyoshi, A. M.
    Chauffaille, M. L. L. F.
    Yamamoto, M.
    Chiba, A. K.
    Kimura, E. Y. S.
    Bordin, J. O. B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 280 - 281
123